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S U M M A R Y
Objectives: Hepatitis B virus (HBV) infection with undetectable hepatitis B surface antigen (HBsAg) has
been reported in HIV patients, but the clinical signiﬁcance is unknown. This study presents the
prevalence of HBV DNA in HIV-positive patients negative for all HBV serological markers and a
retrospective evaluation of the clinical course of mono- and co-infection.
Methods: Of 502 HIV-positive patients, 222 tested negative for HBsAg, antibody to hepatitis B surface
antigen (anti-HBs), and antibody to hepatitis B core antigen (anti-HBc). An in-house real-time PCR
targeting the HBV S-region was used to quantify HBV DNA. HBV isolates were genotyped. Baseline
demographic and clinical characteristics of HBV DNA-positive and HBV DNA-negative patients were
described. Treatment outcomes of patients at 6, 12, and 24 months after initiation of antiretroviral
therapy (ART) were summarized.
Results: HBV DNA was detected in 5.4% (12/222) of serologically negative patients. Mean HBV viral load
was 5359.2 IU/ml (standard deviation (SD) 12 768.27). Eleven HBV isolates belonged to genotype A and
one to genotype C. There were no signiﬁcant differences in baseline characteristics or clinical course between
the HBV DNA-positive and HBV DNA-negative groups.
Conclusions: We found 5.4% of the HBV serologically-negative HIV-positive patients had low levels of
HBV DNA. There were no signiﬁcant differences in clinical outcome between the mono- and co-infected
groups.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Between 5% and 17% of HIV-infected patients in South Africa are
co-infected with hepatitis B virus (HBV).1–3 Co-infection with HBV
has been shown to increase mortality rates from 1.7 per 1000
person-years to 14.2 per 1000 person-years as a result of liver
disease in HIV-infected men.4 Moreover, HBV infection can
complicate the treatment of HIV patients on antiretroviral therapy
(ART). The risk of ART toxicity is increased threefold,4,5 and this risk
further increases when patients are taking concomitant medica-
tions for tuberculosis (TB).2
In South Africa, HBV DNA has been detected in hepatitis B
surface antigen (HBsAg)-negative HIV-infected patients.6–8 In
these studies, the HIV-infected patients were positive for isolated
antibody to hepatitis B core antigen (anti-HBc). The clinical* Corresponding author. Tel.: +27 11 276 8800; fax: +27 11 482 2130.
E-mail address: cindy.ﬁrnhaber@righttocare.org (C. Firnhaber).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.12.007signiﬁcance of HBV DNA in the setting of HBsAg-negative serology
is controversial. Some studies have found that the presence of HBV
DNA in HIV-infected patients, in the absence of HBsAg, does not
increase the frequency of transaminitis and hepatic ﬂares.9,10
Others have shown only minimal hepatocellular inﬂammation;11
and yet others have shown statistically signiﬁcant increases in
hepatitis ﬂares.12 Confounding factors including ethnicity and
variation in the prevailing HBV genotypes may account for these
differences.
At present, there is very little information regarding the clinical
course of HBV DNA-positive, HBsAg-negative HIV-infected
patients from Africa. It is important that this is studied because
the strains of HBV13 and HIV14 prevailing in Africa differ from those
found in other regions of the world. The classiﬁcation of HBV into
eight genotypes, A to H, with a distinct geographic distribution15 is
well established, and a ninth genotype, I, has recently been
identiﬁed and characterized.16–21 In Africa, genotypes A, D, and E
have been isolated and a geographical distribution demonstrated,
with genotype A found in southern eastern Africa, genotype D inses. Published by Elsevier Ltd. All rights reserved.
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Evidence in this ﬁeld from non-African countries may thus not
necessarily be extrapolated to Africa. The objective of this sub-
study of previous work,1,8 was to determine the prevalence of HBV
DNA in HBV serologically-negative HIV-positive patients and to
evaluate the clinical impact of co-infection with HBV in this
population.
2. Methods
2.1. Patient selection
Between 2006 and 2007, eligible HIV-positive patients initiat-
ing ART at the Themba Lethu Clinic (located in a secondary-level
government academic hospital in Johannesburg) were invited to
participate in the study. The study participants were educated
about HBV/HIV co-infection and ART. Enrolment criteria included
treatment-naı¨ve patients who were aged 18 years and older and
who were about to initiate lamivudine (3TC)-containing ART in
accordance with public sector guidelines (i.e., a CD4 count <200
cells/mm3 and/or World Health Organization (WHO) clinical stage
4).22 None of these patients had received vaccination against HBV,
because universal HBV vaccination at 6, 10, and 14 weeks of age
was only introduced into the South African Expanded Programme
on Immunization (EPI) in 1995 and therefore none of the
participants would have received any vaccination. A total of 502
people agreed to participate in this study and signed informed
consent. The parent study and cohort characteristics are described
elsewhere.1
The study was approved by the Human Research Ethics
Committees (Medical) of the University of the Witwatersrand
and Saint Louis University Internal Review Board. Reasons for non-
participation included additional time needed for HBV education,
informed consent, poor understanding of the study, refusal to have
extra blood drawn, and feeling too ill to participate.
2.2. Laboratory tests for HBV
2.2.1. HBV serology
This included qualitative testing for HBsAg, hepatitis B e antigen
(HBeAg), antibody to hepatitis B surface antigen (anti-HBs),
antibody to hepatitis B e antigen (anti-HBe), and anti-HBc, using
the Axsym assays (Abbott Laboratories, IL, USA).
2.2.2. DNA extraction
DNA was extracted from 222 of the 502 serum samples that
tested negative for HBsAg, HBeAg, anti-HBs, anti-HBe, and anti-
HBc. DNA was extracted from 200 ml of serum using the QIAamp
MinElute Virus Spin Kit (Qiagen GmbH, Hilden, Germany), in
accordance with the manufacturer’s instructions, and eluted into
200 ml elution buffer.
2.2.3. Real-time PCR quantiﬁcation of HBV DNA
PCR primers, HBV-Taq1 and HBV-Taq2, as well as the FAM/
TAMRA labeled TaqMan BS-1 probe were used,23 and real-time PCR
quantiﬁcation of HBV DNA performed as described previously.7 A
serial dilution of cloned plasmid DNA containing a single genome
of HBV DNA, ranging from 5  102 to 5  107 IU/ml in concentra-
tion, was used as template to generate the standard curve. The
linear standard curved obtained was in agreement with the
previous reports for this primer/probe set. The second WHO
International Standard for HBV Nucleic Acid Ampliﬁcation
Techniques (product code 97/750 National Institute for Biological
Standards and Controls (NIBSC); Hertfordshire, UK), which has a
ﬁnal concentration of 1  106 IU/ml, was used as the internal
standard. The standard curve, blank, positive and negativecontrols, and samples were all tested in duplicate. The measured
IU/ml for each reaction was calculated using the Ct (cycle
threshold) value of each PCR interpolated against the linear
regression of the standard curve. The dynamic range of the in-
house real-time PCR was 5  102 to 5  107 IU/ml (2 logs to 7 logs
of linear dynamic range).
2.2.4. HBV genotyping
Only samples that were HBV-DNA-positive for two separate
real-time PCR reactions were genotyped. A restriction fragment
length polymorphism (RFLP) assay was used to genotype HBV
isolates.24 Primers P7 and P8 were used to amplify nucleotides 256
to 796 (from the EcoRI site) in the S region. The amplicon was
cleaved using restriction enzymes HinfI and Tsp509I, in separate
reactions, to give the characteristic RFLP patterns for the different
genotypes.24
2.3. Clinical course
The 2-year clinical course of 211 of 222 HBV serologically-
negative HIV-positive patients was evaluated retrospectively by
ﬁle review through the TherapyEdge-HIV (TE)TM electronic patient
management system. The evaluation reviewed HIV clinical adverse
events (i.e., TB, ART side-effects), HIV monitoring, and routine
safety laboratory parameters (CD4 count, HIV viral load, liver
transaminases, and full blood count). Hepatic ﬂare was deﬁned as
any elevation of liver transaminases with clinical signs of hepatic
injury or any asymptomatic elevation greater than two times the
upper limit of the normal range.
2.3.1. Statistical analysis
Baseline demographic and clinical characteristics of HIV-
positive patients with and without HBV DNA were described.
Differences in clinical and laboratory responses at three time-
points after ART initiation (6, 12, and 24 months) were estimated
using the Student’s t-test (parametric), the Kruskal–Wallis test
(non-parametric), and the Wilcoxon test (non-parametric) for
continuous variables, and the Chi-square test for proportions.
Mortality was ascertained via South Africa’s National vital
registration system, and lost to follow-up (LTFU) was deﬁned as
having missed a clinic appointment (clinical assessment, anti-
retrovirals pickup, counselor visit) by at least 3 months after the
scheduled visit date.25 All analyses were performed with SAS
version 9.1 (SAS Institute Inc., Cary, NC, USA).
3. Results
Of the 502 HIV-positive patients enrolled into the parent study,
222 were negative for HBsAg, HBeAg, anti-HBs, anti-HBe, and anti-
HBc. Thus 44% were HBV serologically-negative. Baseline demo-
graphics and characteristics of the HBV DNA-positive patients
were similar to patients who were positive for anti-HBc from the
larger study7 in terms of age (mean  SD, 34.2  5.43 years vs.
39.98  11.64 years), gender (female 60% vs. 56%), and CD4 count
(mean  SD, 91  73.2 cells/mm3 vs. 49  77.2 cells/mm3) (all p-
values >0.05).
Of the 222 patients who were HBV serologically-negative, 12
(5.4%) tested positive for HBV DNA in duplicate real-time PCR HBV
DNA quantiﬁcation assays. The mean HBV viral load before
initiating ART was 5359.2 (SD  12 768.27) IU/ml. Eleven HBV
isolates belonged to genotype A and one to genotype C.
The clinical course of 211 of the 222 HBV-serologically-negative
patients was evaluated retrospectively. The ﬁles of 11 patients
could not be located on the TE management system and were
declared LTFU. Two of these missing ﬁles were from patients with
positive HBV DNA, thus leaving 10 HBV-positive patients evaluable
Table 1
Baseline demographic and clinical characteristics of HBV DNA-negative and HBV DNA-positive patients (N = 211)
HBV DNA-negative HBV DNA-positive p-Value
Patients n = 201 (95.3%) n = 10 (4.7%)
Age at initiation (years), median (IQR) 35.1 (31.8–42.2) 33.9 (28.8–34.9) p = 0.201a
Sex, female 149 (74%) 6 (60%) p = 0.323b
ALT (IU/l), median (IQR) 22 (16–33) 26 (20–47) p = 0.245a
>40 IU/l 24/163 (15%) 2/8 (25%) p = 0.429b
AST (IU/l), median (IQR) 32 (25–42) 43 (30–55) p = 0.137a
> 40 IU/l 44/160 (28%) 4/8 (50%) p = 0.169b
CD4 cell count (cells/mm3), median (IQR) 108 (50–149) 89 (37–187) p = 0.796a
<100 cell/mm3 78/162 (48%) 4/8 (50%) p = 0.916b
TB at ART initiation 13 (6%) 1 (10%) p = 0.178b
First ART regimen
d4T/3TC/EFV 138 (80%) 8 (89%) p = 0.448b
d4T/3TC/NVP 11 (6%) 1 (11%) p = 0.546b
Other regimen 25 (14%) - p = 0.240b
HBV, hepatitis B virus; IQR, interquartile range; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TB, tuberculosis; ART, antiretroviral therapy; d4T, stavudine;
3TC, lamivudine; EFV, efavirenz; NVP, nevirapine.
Data are n (%) unless otherwise indicated.
a p-Value obtained from t-test or Kruskal–Wallis.
b p-Value obtained from Chi-square test for associations.
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of ART, the demographic characteristics of the participants with
HBV DNA (n = 10) did not differ from those without HBV DNA
(n = 201) (Table 1). Both groups were similar in terms of age,
gender, liver function tests, and ﬁrst ART regimen. The baseline
median CD4 cell count was 89 cells/mm3 (IQR 37–187) in the HBV
DNA-positive group and 108 cells/mm3 (IQR 50–149) in the HBV
DNA-negative group; the difference was not statistically signiﬁ-
cant. All participants were negative for HCV by PCR assay.1
Out of the 211 patients, 183 (87%) initiated ART. Of the 28
patients who did not start ART, 19 were LTFU, one died of unknown
causes, and one transferred to another clinic. Seven started ART in
late 2009 to 2010 after the study period. The majority of patients,
80% (146/183), who started ART were on regimen 1a: stavudine
(d4T), lamivudine (3TC), and efavirenz (EFV). The majority (89%) of
patients with isolated HBV started regimen 1a. No patients
received tenofovir as it was not available in government sectorTable 2
Clinical and laboratory responses at 6, 12 and 24 months after initiation of ART
Variable Clinical and laboratory resp
HBV DNA-negative 
Baseline to
6 months
6 to
12 mon
Number with follow-up available 174 162 
AST (IU/l), median (IQR) 28 (22–40) 27 (21–
AST >40 IU/l 35/144 (24%) 15/100 
ALT (IU/l), median (IQR) 24 (16–35) 21 (15–
ALT >40 IU/l 28/148 (19%) 18/98 (1
CD4 cell count (cells/mm3), median (IQR) 227 (153–324) 243 (18
Number of ART substitutions or regimen switch, yes 23 (13%) 31 (19%
Reason for ART change known
Peripheral neuropathy 1 2 
Lactic acidosis/hyperlactatemia 1 0 
Toxicity (not speciﬁed) 1 0 
Virological failure 0 2 
Pregnancy 0 0 
Outcomes of ART patients (NS)
Alive, on treatment 162 (93%) 147 (84
Dead 1 (0.6%) 6 (3%) 
Lost to follow-up 6 (3.4%) 13 (8%) 
Transferred to another facility 5 (3%) 8 (5%) 
ART, antiretroviral therapy; HBV, hepatitis B virus; IQR, interquartile range; AST, aspar
signiﬁcant.
Data are n (%) unless otherwise indicated.
a p < 0.001 by t-test (parametric).
b p < 0.001 by Wilcoxon test (non-parametric).care during the time of this study. By the end of study follow-up,
84% (n = 154/183) of all study participants were alive and in care
(Table 2). There were no events reported that were clinically
consistent with hepatic ﬂare in either group. No deaths were
recorded among the HBV DNA-positive group, while 4% (n = 7) of
those without HBV DNA had died over the course of 24 months of
follow-up. The proportion lost to follow-up was not statistically
signiﬁcant.
The median CD4 cell counts were similar at each time-point
evaluated for both groups (Table 2). The proportion of patients who
switched antiretrovirals was the same in both groups (43% vs. 39%)
and these switches occurred earlier for the HBV DNA-positive
group (33% vs. 13% by 6 months), but this was not statistically
signiﬁcant. Among all patients who experienced a treatment
switch, one of the most common reasons was peripheral
neuropathy (Table 2). HBV viral loads and genotypes were not
determined in the follow-up samples.onses
HBV DNA-positive
ths
12 to
24 months
Baseline to
6 months
6 to
12 months
12 to
24 months
147 9 8 7
35) 22 (19–30) 26 (24–33) 24 (19–25)a 38 (25–43)b
(15%) 14/77 (18%) 0 0 1/3 (33%)
35) 21 (16–27) 23 (10–37) 19 (16–21)a 26 (12–36)
8%) 7/77 (9%) 2/8 (25%) 0 0
8–333) 329 (204–428) 167 (78–399) 150 (62–312) 78 (68–399)
) 58 (39%) 3 (33%) 3 (38%) 3 (43%)
0 0 0 1
1 0 0 0
1 1 0 0
2 0 0 1
3 0 0 0
%) 140 (81%) 8 (89%) 8 (89%) 7 (78%)
7 (4%) 0 (0%) 0 (0%) 0 (0%)
18 (10%) 1 (11%) 1 (11%) 2 (22%)
9 (5%) 0 (0%) 0 (0%) 0 (0%)
tate aminotransferase; ALT, alanine aminotransferase; NS, results not statistically
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Three South African studies have previously demonstrated HBV
DNA in 33%,6 88.5%,7 and 10%8 of isolated anti-HBc-positive HIV-
infected patients. To our knowledge, this is the ﬁrst African study
to evaluate HBV DNA prevalence and the clinical course in HIV-
infected patients without any serological markers for HBV. Of the
502 original serum samples screened, 222 (44%) had no HBsAg,
HBeAg, anti-HBs, anti-HBe, and anti-HBc. A subset of 12 samples
were considered HBV DNA-positive only when they tested positive
in duplicate re-extracted real-time PCR assays, as well as in the
subgenomic qualitative PCR used for genotyping.24 The use of this
stringent criterion as well as strict control measures in the
laboratory,26 preclude the possibility that the detection of HBV
DNA was the result of contamination.27
The majority of HBV isolates belonged to genotype A, which is
consistent with the genotypes found in South Africa.13,28 The
presence of HBV genotype C in one individual is unusual, but could
be a result of the increased inﬂux into South Africa of emigrants
from Southeast Asia, where HBV genotypes B and C circulate.15
HBsAg-negativity despite detectable HBV DNA can be as a result of
the presence of mutants that affect expression and hence detection
of HBsAg;29–31 low HBV replication leading to low levels of
HBsAg,29 below the detection limit of the serological assays; and
the formation of immune complexes, which mask the HBsAg
epitopes preventing detection.32 Following immune reconstitution
as a result of ART, one study found 4/65 (6.2%) patients regained
HBsAg.33 The absence of anti-HBs may be a result of the
immunocompromised state of the patients studied.34,35 Increased
CD4 counts following ART have been shown to be associated with
the reappearance of anti-HBs.33,34 The absence of anti-HBs has
previously been shown to be a risk factor for the detection of HBV
DNA in isolated anti-HBc-/HIV-positive patients.35
In the present study, the median CD4 count among the HBV
DNA-positive group was 20 cells/mm3, lower than that of the HBV
DNA-negative patients. Although these low CD4 counts were not
signiﬁcantly associated with the detection of HBV DNA in the
present study and another published study,35 a signiﬁcant
association was found between lower CD4 counts in HBsAg-
negative/isolated anti-HBc-positive HIV-infected patients in an-
other study.36 Detectable HBV may be as a result of reactivation of
HBV infection following immunosuppression,36 or a functional T
cell defect.35 Given this possible dynamic relationship between
immune status, HBV DNA and HBV serology, repeat serological and
HBV DNA measurements should be considered (if feasible and
clinically indicated) to accurately assess the patient’s current HBV/
HIV co-infection status.
We demonstrated little difference in clinical outcomes between
the HBV DNA-positive and HBV DNA-negative groups, although
the small sample size may be a limitation in our ability to detect
statistically signiﬁcant differences. These ﬁndings are however
consistent with a previous work by Shire and colleagues, who also
failed to identify any factors that distinguish HBV DNA-positive
HBV serologically-negative HIV patients from other HBV DNA-
positive HBsAg-negative patients with isolated anti-HBc.27 There
may be a number of reasons for this in the present study. Firstly,
the mean HBV viral load was quite low at 5359.2 IU/ml and may
not have been a high enough burden to cause complications.
Secondly, all these patients were started on an ART regimen
containing lamivudine, which could have easily suppressed the
HBV quickly, thus preventing complications as a result of the viral
infection. Thirdly, while there is an increased risk of ART toxicity in
HIV patients co-infected with HBV, severe hepatotoxicity (alanine
aminotransferase more than ﬁve times normal) is rare.37 In this
population, the numbers may have been too small to demonstrate
a serious adverse event.Our results should be interpreted in light of the possible
limitations of this study. Firstly, the small sample size may have
limited our ability to detect differences. Secondly, this study
retrospectively analyzed observational data and so we cannot
exclude the possibility of bias. Finally, this sample is from one
academic facility in Johannesburg, South Africa, and as such,
results may not be generalizable to other settings, particularly
settings in the developed world. Despite these limitations, our
results add evidence to a limited body of knowledge in the ﬁeld.
Additionally, this study was carried out in the setting of an
implementation government HIV treatment clinic and not the
strict environment of a clinical trial. As such, these results may
possibly reﬂect the practical clinical experience of HBV serology-
negative DNA-positive individuals more closely.
Although there appears to be a lack of clinical signiﬁcance of HBV
DNA in HBV serologically-negative HIV patients in our setting, there
are a number of other considerations that need to be taken into
account in clinical practice. HBV DNA can be transmitted by blood
donation and liver transplantation, can reactivate, and has been
implicated in the development of hepatocellular carcinoma.38As has
been shown in this and other studies,27,33,39 HBV serological tests
alone may not be sufﬁcient to detect HBV infection in HIV-infected
individuals. Sensitive PCR assays are needed to detect HBV DNA, but
these are often not available or feasible in resource-limited
environments. Implementation of alternative measures such
comprehensive HBV vaccination and early initiation of ART should
be considered to prevent possible opportunistic reactivation of HBV
infection, transmission of HBV to uninfected individuals, and the
potential development of HBV-related liver disease.
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